Search Hotels in Sausalito

As the calendar turns toward 2026, the exuberant "AI-everything" rally that defined much of 2024 and 2025 is facing a sobering reality check. With the Federal Reserve entering a delicate transition...

Topics Fraud

The 2022 Playbook Returns: Why Investors are Building a 'Fortress 2026'

December 18, 2025

Worried About the Stock Market in 2026? These 3 Stocks Did Well During the Last Bear Market. ↗

Topics Artificial Intelligence Economy World Trade

December 18, 2025

The stocks listed here were all up more than 19% in 2022, while the S&P 500 crashed.

New Obesity Medicine Association Initiative Aims to Scale High-Impact Obesity Healthcare Improvements Nationwide

Topics Intellectual Property Stocks

December 18, 2025

Centennial, Colorado--(Newsfile Corp. - December 18, 2025) - The Obesity Medicine Association (OMA) is pleased to announce a new multi-phase...

Via Newsfile

Eli Lilly’s Oral Obesity Drug Passes Maintenance Test After Wegovy, Zepbound — Wall Street Flags Win For Viking Therapeutics ↗

December 18, 2025

Lilly’s Orforglipron is eligible for a fast-track review by the FDA in treating obesity.

Via Stocktwits

Better Buy in 2026: Pfizer or Eli Lilly? ↗

December 18, 2025

These two stocks have been going in opposite directions over the past few years.

NEW YORK — In a stunning reversal of the "higher-for-longer" narrative that dominated much of 2025, the Bureau of Labor Statistics released its November Consumer Price Index (CPI) report today,...

Topics World Trade

Main Street’s High-Stakes Gamble: Retail Traders Double Down as Inflation Cools to 2.7%

December 18, 2025

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.2% in the morning session after the company released positive data from its Phase 3 "ATTAIN-MAINTAIN" trial, which evaluated the...

Topics Artificial Intelligence Economy Regulatory Compliance

Why Eli Lilly (LLY) Stock Is Trading Up Today

December 18, 2025

Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.

After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss ↗

December 18, 2025

Via Benzinga

The Weight of a Trillion: Inside Eli Lilly’s Pharmaceutical Hegemony

December 18, 2025

On this day in late 2025, Eli Lilly and Company (NYSE: LLY) stands as the undisputed titan of the global pharmaceutical industry. Having crossed the historic $1 trillion market capitalization threshold...

Via PredictStreet

Topics Economy World Trade

Eli Lilly's Weight-Loss Pill Succeeds In A First-Of-Its-Kind Study ↗

December 18, 2025

Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the weight off.

Via Investor's Business Daily

Eli Lilly Scores Another Major Win: Time to Buy? ↗

December 18, 2025

The company is running circles around its competition.

These two healthcare stocks have strong growth prospects, but they've been going in opposite directions.

Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk ↗

December 18, 2025

It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.

The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now ↗

December 17, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Topics Intellectual Property

1 Cash-Producing Stock for Long-Term Investors and 2 We Brush Off

December 16, 2025

These three growth stock-heavy ETFs offer a contrarian way to invest in a potential stock market sell-off.

3 Unstoppable Vanguard ETFs to Buy Even if There's a Stock Market Sell-Off in 2026 ↗

December 16, 2025

New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall...

Topics Artificial Intelligence ETFs Economy

Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector

December 16, 2025

Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it.

Topics Intellectual Property

1 Bold Prediction for Viking Therapeutics in 2026 ↗

December 16, 2025

Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio.

Is Eli Lilly a Buy Before 2026? ↗

December 16, 2025

Profit Powerhouse: Strong Earnings Outlook Defies Market Slips, Signaling Continued Bull Run for US Stocks

December 16, 2025

Despite recent pockets of volatility and "slips" in the U.S. stock market during late 2025, a robust corporate profit outlook is emerging as a powerful counter-narrative, fueling investor optimism and...

Novo Nordisk's stock has dropped 41% YTD as it lowered sales growth and trimmed 2025 guidance due to competition and patent expiration.

Topics Artificial Intelligence Economy Stocks

3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most ↗

December 16, 2025

Via MarketBeat

Pfizer Adds to Its Big Bet on Weight Loss Drugs ↗

December 16, 2025

Via MarketBeat

Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars ↗

December 16, 2025

Via Benzinga

Topics Intellectual Property

Where Will Eli Lilly Be in 10 Years? ↗

December 16, 2025

In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today.

Can anything stop this high-flying drugmaker?

Topics Intellectual Property

2 Predictions for Eli Lilly in 2026 ↗

December 15, 2025

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the stock benefited as investors rotated capital out of the volatile technology sector and into...

Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years ↗

December 15, 2025

Via Benzinga

Why Eli Lilly (LLY) Stock Is Trading Up Today

December 15, 2025

Eli Lilly's Obesity Drug Dominance Still Underpriced By Market, Bank of America Says ↗

December 15, 2025

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Via Benzinga

Eli Lilly Just Delivered Fantastic News to Investors ↗

December 15, 2025

Eli Lilly shares have climbed in the double digits this year.

Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)

December 14, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers.